Mamapop has funded 4 lines of research at the IRBLleida into the HER2 variant of breast cancer

Thanks to the initiative, more than 140,000 euros have been raised for breast cancer research

The Mamapop solidarity concert has funded 4 lines of research at IRBLleida into the HER2 variant of breast cancer. Thanks to the initiative, 146,779 euros have been contributed to breast cancer research. This research has benefited around 50 people each year who have been diagnosed with HER2 breast cancer. This was explained today by the doctor from the Medical Oncology Service of the Arnau de Vilanova University Hospital of Lleida (HUAV) and principal investigator of the Biomarkers in Cancer Research Group (GReBiC) of the Biomedical Research Institute of Lleida (IRBLleida), Serafín Morales Murillo, accompanied by the promoter and artistic director of Mamapop, Manel Simón Barbero.

Specifically, the benefits of Mamapop, which this year will celebrate its 7th edition, have allowed the following 4 lines of research to be carried out at IRBLleida:

  • Project to study mRNA expression as a predictor of response to adjuvant treatment.
  • Project to study the expression of primary TILS as a predictor of response to adjuvant treatment.
  • Project for mutational analysis of HERS2+ tumours.
  • Project to study the confirmation of the genomic platform as a predictor of response and prognosis.

On the other hand, as Serafín Morales explained, in addition to the projects, the research also includes clinical trials, most of which are financed by the pharmaceutical industry. Within the framework of these trials, the appmiclinica application for breast cancer patients participating in clinical trials has been promoted, a reliable and contrasted information tool that allows users to keep up to date with the latest news and avoid confusion in the face of the large amount of information.

One of the latest developments in the field of clinical trials is the incorporation, scheduled for December, of the use of two new drugs for the treatment of breast cancer: Trodelevy (Sacituzumab Govitecan) and Enhertu (trastuzumab deruxtecan). The first drug has shown great efficacy in patients with metastatic triple negative breast cancer that had progressed and the second has shown great benefit in patients with HER2+ metastatic breast cancer who have progressed to various lines of treatment. The use of these two drugs represents a new breakthrough in this type of tumour with a more targeted action.

It should be remembered that patients with metastatic stage breast cancer at the Hospital Universitario Arnau de Vilanova (HUAV) are participating in a new clinical trial with very active drugs in this stage that help to improve the prognosis of this type of breast cancer, as reported in a press release on 19 October, World Breast Cancer Day.

The 7th edition of Mamapop marks the resumption of the concert after a two-year hiatus due to the Covid-19 pandemic. It comes with the ambition and desire to be the best version of its history with a demanding proposal of high quality that will review the best songs of the most important artists of Latin music. This year there will be three sessions, Saturday 26 November at 7 p.m. and 10 p.m., and Sunday 27 November at 7 p.m., at the Llotja de Lleida. Ticket sales are progressing well, and the Saturday session at 7 p.m. is already full. Tickets are still available for the rest of the sessions.

The member of the Mamapop Organising Committee, Manel Tahull; the doctor from the HUAV Medical Oncology Service, Serafín Morales; and the promoter of Mamapop, Manel Simón